Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

MoonLake Immunotherapeutics has done well to develop the use of its drug Sonelokimab in the ongoing phase 3 VELA program, which is using this IL-17A/IL-17F inhibitor to target patients with ...

With upgraded visa policies and smart services, Ningbo is poised to become China’s next top inbound destination.

Investing.com -- Shares of MoonLake Immunotherapeutics soared 21.5% following reports that Merck (NSE:PROR) has engaged in discussions regarding a potential acquisition of the Swiss biotech firm ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.

Moonlake is running phase 3 studies of the nanobody in psoriatic arthritis and advancing the drug candidate toward pivotal trials in psoriasis, palmoplantar pustulosis and axial spondyloarthritis.

MoonLake Immunotherapeutics shares are currently trading up about 18.7% on the day. The chart below shows the one year performance of MLTX shares, versus its 200 day moving average: ...

MoonLake Immunotherapeutics’ lead development asset sonelokimab is a Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report Skip to main content ...

MoonLake's shares rose 19% in extended trading. Merck submitted a nonbinding offer for MoonLake earlier this year, according to the report, which added that the initial approach was rejected but ...